Antony C Willis

Title: Antony C Willis: Innovator in Diabetes Research

Introduction

Antony C Willis is a notable inventor based in Witney, GB. He has made significant contributions to the field of diabetes research, particularly through his work on amylin peptides. His innovative approach has led to advancements in understanding and treating Type 2 diabetes.

Latest Patents

Willis holds a patent for "Amylin peptides," which are biologically active peptides associated with diabetes. The patent discloses processes for preparing and assaying these peptides, which include the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY. The invention encompasses not only the peptides themselves but also substantially homologous sequences, proamylin, and biologically active subfragments. The methods for preparing the peptide involve solubilization of amyloid from diabetic pancreata and isolation through gel filtration and reverse phase chromatography. Additionally, amylin can be synthesized or produced using recombinant DNA techniques.

Career Highlights

Antony C Willis is affiliated with Amylin Pharmaceuticals, Inc., where he has been instrumental in advancing research related to diabetes. His work has contributed to a deeper understanding of the biological mechanisms involved in the disease, paving the way for potential therapeutic applications.

Collaborations

Willis has collaborated with Garth J Cooper, a fellow researcher in the field. Their partnership has fostered innovation and has been crucial in the development of new approaches to diabetes treatment.

Conclusion

Antony C Willis is a key figure in diabetes research, with a focus on amylin peptides that hold promise for improving treatment options for Type 2 diabetes. His contributions through patents and collaborations highlight the importance of innovation in addressing complex health challenges.